Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare specializes in oncology and autoimmune drugs.
Eli Lilly’s AtaiBeckley acquisition marks a dozen M&A deals for the pharma company so far this year. AtaiBeckley’s lead program is an intranasally administered psychedelic drug in pivotal testing for treatment-resistant depression.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
Eli Lilly made good on its threat to withhold 340B drug discounts from hospitals that refused to submit claims data. Hospital groups are calling the policy unlawful, arguing that the company has no legal authority to create its own compliance requirements for a federal program.
Eli Lilly presented encouraging Phase 1 results for AJ1-11095 at the European Hematology Association (EHA) annual meeting in Stockholm. The drug, a type II JAK2 inhibitor in development for myelofibrosis, came from Lilly’s acquisition of biotech startup Ajax Therapeutics.
Clinical AI startup Abridge held a New York City event to signal it's done being thought of as just an AI scribe. The company announced a Nvidia foundation model partnership, an Eli Lilly investment, new capabilities for its platform, and the intent to help mediate the relationship between payers and providers.
Eli Lilly is spending up to $3.8 billion to buy vaccines in development for shingles, staph infections, and Epstein-Barr virus as well as the platform technologies that spawned these programs. The pharmaceutical giant indicated interest in infectious disease last year when it hired Peter Marks, former director of the FDA division that oversees vaccines.
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Eli Lilly’s retatrutide set a high mark in weight loss for obesity drugs, but with clinical trial results that show some new side effects. More detailed data from the Phase 3 study are scheduled for presentation next month during the American Diabetes Association Scientific Sessions meeting.
Engage Bio developed a platform technology that enables non-viral delivery of DNA to cells. The acquisition is the latest in a series of Eli Lilly deals that expand the pharmaceutical company’s pipeline and capabilities in genetic medicines.
Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal complements Lilly’s acquisitions of Verve Therapeutics and Orna Therapeutics in the past year, each taking different approaches to developing in vivo genetic medicines.
Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
FDA approval for Eli Lilly’s oral GLP-1 drug, Foundayo, comes about three months after Novo Nordisk launched its Wegovy pill. While clinical trial results for both daily pills showed comparable weight reduction, Lilly’s pill offers patients a slight dosing advantage.
Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agonist drug developers that includes Takeda Pharmaceutical, Alkermes, and Eisai.
Eli Lilly’s new Lilly Employer Connect platform offers employers more flexible access to obesity drugs like Zepbound, but experts say it represents only incremental progress.
CSL Limited retains rights to clazakizumab in end-stage kidney disease. Eli Lilly gets rights to the the IL-6-blocking antibody in other indications that could put it in competition with Novo Nordisk and Novartis.
Elli Lilly has been in the news lately because of the announced $1 billion investment in a joint innovation lab with Nvidia, an AI powerhouse player. But AI drug discovery is only part of the story of where AI can be leveraged in biopharma.